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PilocarpineDuring the epileptogenic process, several events may occur, such as an important activation of the immune sys-
tem in the central nervous system. The response to seizure activity results in an inﬂammation in the brain aswell
as in the periphery. Moreover, CRP and cytokines may be able to interact with numerous ligands in response to
cardiac injury caused by sympathetic stimulation in ictal and postictal states. Based on this, we measured the
serum levels of C-reactive protein (CRP) and cytokines during acute, silent, and chronic phases of rats submitted
to the pilocarpine model of epilepsy. We have also analyzed the effect of a chronic treatment of these rats with
omega-3 fatty acid in CRP and cytokine levels, during an epileptic focus generation. C-reactive protein and cyto-
kines such as IL-1β, IL-6, and TNF-α presented high concentration in the blood of rats, even well after the
occurrence of SE. We found reduced levels of CRP and all proinﬂammatory cytokines in the blood of
animals with chronic seizures, treated with omega-3, when compared with those treated with vehicle solution.
Taken together, our results strongly suggest that the omega-3 is an effective treatment to prevent SUDEP occur-
rence due to its capability to act as an anti-inﬂammatory compound, reducing the systemic inﬂammatory param-
eters altered by seizures.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Several lines of evidence have shown the involvement of inﬂamma-
tory pathway with temporal lobe epilepsy (TLE) [1–3]. Patients with
speciﬁc forms of epilepsy present with a peripheral inﬂammatory re-
sponse linked to the condition; furthermore, an increased cytokine re-
sponse has also been reported in the literature in these cases [4].
Another event that occurs during long-lasting seizures is dysfunc-
tion of the blood–brain barrier (BBB) [5,6], allowing the entrance of
proteins and cells from the blood into the brain, increasing local inﬂam-
mation, and amplifying excitability in a continuous cycle. In this context,
lymphocytic inﬁltrate and high cytokine levels suggest that both
humoral and cellular immune systems are exacerbated in these patients
[2].
C-reactive protein is an important molecule related to the acute
phase of the inﬂammatory process; it is present in the serum or plasmao Paulo, SP 04039032, Brazil.
Naffah-Mazzacoratti).of many vertebrates [7]. Its main effect is the modulation of several cas-
cades related to immune system activation [8]. It has been linked to in-
ﬂammatory processes, it has been used clinically as a marker for
immune responses to infections, and it has an important biological
role in the pathogenesis of cardiovascular disease [9]. Transcriptional
regulation of CRP has been extensively studied in vitro and in vivo. For
this regulation, several evidences suggest that IL-6 is the principal in-
ducer of the CRP gene expression, while IL-1, TNF-α, glucocorticoids,
and activated complement act synergistically with IL-6 to enhance its ef-
fect [10–12]. An increased CRP level in the blood is considered to be an
inﬂammatory marker for brain ischemia, stroke, and vascular events
[13].
A few studies provided clinical and experimental evidence suggest-
ing that omega-3 fatty acid supplementation decreases the duration
and frequency of seizures [14–16], resulting in neuroprotective effects
against seizure-induced brain damage [17]. In patients with refractory
seizures, it has been suggested, though not proven, that treatment
with omega-3 fatty acid could also reduce seizure-associated cardiac ar-
rhythmias and, in some cases, sudden unexpected death (SUDEP), the
most important direct epilepsy-related cause of death [18,19].
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the immune system in epilepsy; therefore, the main objective of this
study was to investigate CRP, IL-1β, TNF-α, IL-6, and IL-10 levels in
the blood of rats submitted to the pilocarpine of temporal lobe epilepsy.
This model consists of an acute phase, characterized by long-lasting sta-
tus epilepticus (SE) (12 h), followed by a silent period with no seizures
(lasting 4 to 44 days) culminating in a chronic phase (period of sponta-
neous seizures), lasting for the rest of the animal's life [20]. We also an-
alyzed the levels of these immunological markers in the blood of
epileptic rats (chronic phase), daily treated with omega-3 fatty acid,
after SE onset.
2. Material and methods
2.1. Animals and status epilepticus induction
The animal experiments were performed under UNIFESP Institutional
Ethical Committee approval (Hospital São Paulo/Universidade Federal de
São Paulo, process n. 313162), and all efforts were made to minimize
animal suffering. Wistar adult male rats, weighing 250 g, were housed
in groups of three to four per cage and maintained in controlled room
temperature, humidity, and light–dark cycle (12:12 h) with chow
pellets and tap water available ad libitum.
The rats received a single dose of pilocarpine (350 mg/kg, intraperi-
toneal [i.p.]). To prevent peripheral cholinergic effects, scopolamine
methylnitrate was injected subcutaneously at a dose of 1 mg/kg,
30 min before pilocarpine administration.
To stop status epilepticus (SE) during the acute phase of the pilocar-
pine model, diazepam (10 mg/kg, Cristalia-Compaz) was administered
subcutaneously 3 h after SE onset. The animals were then allowed to
evolve from the acute to the silent and chronic phases of this model as
previously reported byus [20]. The occurrence of spontaneous recurrent
seizures (SRSs) during the chronic period was video-monitored (24 h
per day) for 90 days. Animalswere sacriﬁced, and the bloodwas collect-
ed for CRP and cytokine assay.
2.2. Animal groups
2.2.1. C-reactive protein
To study the inﬂuence of long-lasting SE or spontaneous seizures
(chronic period) on peripheral C-reactive protein, the following groups
(n=8)were analyzed: 5 h, 12 h, and 24 h after SE onset (acute period);
48 h and 5 days after SE induction (silent period), and 90 days after SE
onset (chronic phase, period of spontaneous seizures). Saline-treated
animals were used as controls for each group (n = 8) as well as rats
that received pilocarpine but did not develop SE.
2.2.2. Cytokines
To study the inﬂammatory proﬁle (IL-1β, TNF-α, IL-6, IL-10) in
the blood, the following groups were performed: acute (5 h), silent
(5 days), and chronic (90 days after SE onset). These groups were
compared with saline-treated rats (n = 6 each group).
2.2.3. Omega-3 treatment
Rats were submitted to SE, which was blocked with diazepam 3 h
after onset. After that, animals received vehicle cremophor (0.009%) or
ﬁsh oil (omega-3, PROEPA, 85mg/kg/day). These solutionswere admin-
istered to animals between 11:00 and 12:00 am by gavage. The volume
administered was adjusted according to animal weight, which was ver-
iﬁed three times aweek, for 90 days. Omega-3 fatty acidwas formulated
as ﬁsh oil (EPA 180 mg and DHA 120 mg). The capsule contents were
dissolved in cremophor 0.009%, yielding a ﬁnal concentration of
21.25 mg/ml ﬁsh oil, which corresponds to 3.82 mg/ml EPA and
2.55 mg/ml DHA. At the ﬁnal concentration, ﬁsh oil was administered
1 ml per 250 g of animal weight. Animals were killed by decapitation,
and serum was collected and stored at −80 °C for CRP and cytokineanalyses. Four groups were analyzed: control vehicle (animals which
received saline and cremophor), control omega (animals which re-
ceived saline and omega-3), chronic (animals with epilepsy, 90 days
after SE induction), chronic + omega (animals with epilepsy which re-
ceived omega-3 treatment) (n = 6 for each group).
2.3. Measurement of inﬂammatory markers
2.3.1. CRP assay
Quantitative assessment of CRP levels was carried out via ELISA
(C-reactive protein, ELISA kit, Chemicon, Millipore, MA, USA), follow-
ing the manufacturer's recommendations.
2.3.2. Cytokine analysis
Multiplex immunobead assay technology (MAP Milliplex Rat
Cytokine/Chemokine Magnetic Bead Panel Millipore Corp., Billerica,
MA, USA; Magpix and analytical test instrument, Luminex Corp., Austin,
TX, USA) was performed in serum.
2.4. Statistical analysis
The SPSS statistical package version 22.0 (SPSS, Chicago, IL, USA) and
GraphPad version 6.0 were used for statistical evaluation (GraphPad
Software, San Diego, CA, USA). Data are expressed as the mean ± stan-
dard deviation (SD). Given the sample size and the variable distribution,
nonparametric tests were used. Data for three or more independent
groups were analyzed by Kruskal–Wallis test. When signiﬁcant, a
multiple comparison post hoc test was used (Dunn's test). A two-
tailed p-value b 0.05 was chosen as the level of signiﬁcance. Statistical
data are provided in the ﬁgures.
3. Results
3.1. Animal behavior
Pilocarpine administration induced the following behavioral chang-
es: akinesia, facial automatisms, and limbic seizures consisting of fore-
limb clonus with rearing, salivation, and masticatory jaw movements
and falling. This type of behavior built up progressively into motor
limbic seizures that recurred repeatedly, evolving to long-lasting SE as
previously reported [21].
3.2. CRP levels
Control rats presented CRP serum levels ranging from 6.8 ± 1.5 to
10.3 ± 3.3 ng/ml. However, after SE induction, the CRP concentration
rose drasticallymainly after 5 h of SE. During the silent phase, CRP levels
were still high within 2 days after SE and remained higher 5 days after
SE onset. Animals presenting spontaneous seizures (90 days after SE)
showed high CRP concentration, when compared with control levels.
The comparison between all groups is presented in Fig. 1A, which
shows that CRP elevation is not restricted to seizure period. Its level
remained altered in all periods of the epilepsy model induced by
pilocarpine.
There were no differences in CRP levels between controls treated
with vehicle and controls treated with omega-3 fatty acid. Chronic
rats (with spontaneous recurrent seizures) without treatment present-
ed high values, when compared with its proper control groups. In con-
trast, chronic rats treated with omega-3 for 90 days after SE onset
showed decreased levels of this inﬂammatory marker, when compared
with the chronic group. The treatment with omega-3 fatty acid induced
a reduction in CRP levels, but the treatment was not enough to bring
CRP to normal levels. Treated rats showed CRP levels similar to those
values found in animals during the silent period of this epilepsy model
(5 days after SE) (Fig. 1B).
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Fig. 1.A: Plasma C-reactive protein concentrationsmeasured by ELISA during all periods of the pilocarpinemodel of epilepsy. In the acute phase, a signiﬁcant increasewas observed,main-
ly after 5 h; however, this augmentation remained higher after 12 and24hwhen comparedwith the saline-treated group. In silent period, the levels of CRPwere still high,when compared
with the saline-treated group. Interestingly, 90days after SE,when animals presented spontaneous recurrent seizures, these levels increased again,when comparedwith the saline-treated
group. ***p b 0.001. Mean ± SD. B. Plasma C-reactive protein concentrations measured by ELISA during chronic period of the pilocarpine model of epilepsy after omega-3 treatment.
Note the decreased levels of plasma C-reactive protein after omega-3 treatment in the chronic + omega 3 group, when compared with the chronic group that were untreated group.
***p b 0.001. Mean ± SD.
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creased CRP concentration in the blood, when compared with the con-
trol group, and that the treatment with ﬁsh oil reduced its levels.
3.3. Cytokine multiplex analysis
Multiplex analysis was performed by measuring the cytokines as IL-
1β, TNF-α, IL-6, and IL-10 in plasma.
There were increased levels of IL-1β in the 5-hour (p b 0.05) and
90-day groups (p b 0.001). The 5-day group did not present any differ-
ence in plasma IL-1β levels when compared with the saline group
(Fig. 2A).
Plasma TNF-α levels were higher in the 5-day and 90-day groups
(Fig. 2B). The 5-hour group did not show a statistical difference when
compared with the saline-treated group.
The IL-6 analysis showed a signiﬁcant increase in all periods of the
pilocarpine model, especially after 5 days of SE onset (Fig. 2C).
Interleukin-10, a key anti-inﬂammatory cytokine, started to increase
5 days after SE onset, and a signiﬁcant increase was observed in the 90-
day group (chronic period, p b 0.001) when compared with other
groups and the saline-treated group (Fig. 2D).
After omega-3 treatment, plasma levels of all cytokines were re-
duced when compared with the chronic group (rats that exhibited aspontaneous recurrent seizure without omega-3 treatment) (Fig. 3A,
B, C and D). Thus, these results showed an anti-inﬂammatory effect of
this treatment. Rats that received pilocarpine but did not develop SE
showed normal levels of CRP and cytokines (data not shown).
4. Discussion
The present work shows that during the epileptogenic process, the
peripheral immune system is activated. C-reactive protein and cyto-
kines such as IL-1β, IL-6, and TNF-α presented high concentrations in
the blood of rats, even well after the occurrence of SE. These data are
consistent with a relationship between peripheral mediators of inﬂam-
mation and brain excitability. Previous reports have indicated that in
the central nervous system (CNS), cytokines are produced as a response
to various inﬂammatory stimuli and this production may be induced
also by seizure activity [22,23].
Elevated levels of these inﬂammatory mediators in blood were not
due to a possible long-term effect of pilocarpine, as a cholinergic
agent, since we did not observe an increase in CRP levels in the serum
of rats in the group without SE. According to Marchi et al. [24], pilocar-
pinemay activate proinﬂammatory mechanisms and have direct action
on CNS neurons, increasing brain excitability. This effect of pilocarpine
inducing an increase in inﬂammatory markers was not observed here,
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Fig. 2. Plasma cytokine concentrationsmeasured bymultiplex analysis. A: IL-1β levelswere increased in the 5-hour (acute period) and 90-day groups (chronic period), showing the effect
of seizure occurrence on IL-1β levels. B. TNF-α presented an increased level after 5 days in silent period and remained higher after 90 days (chronic period) C. IL-6 started to increase after
5 h and level was increased after 5 days in silent period and remained higher in chronic period (90 days after SE). D: IL-10 started to increase after 5 days (acute group) and presented
higher level after 90 days (chronic group). All groups were compared with the saline-treated group. **p b 0.01, and ***p b 0.001.
303T.L.F. Gouveia et al. / Epilepsy & Behavior 51 (2015) 300–305in contrast to Marchi's report. Furthermore, animals in the chronic
phase, well after exposure to pilocarpine, also showed high levels of
these inﬂammatory mediators.
Our data also indicated that treatment with omega-3 fatty acids, be-
ginning close to a brain insult (SE), could reduce blood CRP and cytokine
levels, demonstrating that these fatty acids may reduce inﬂammation
after SE onset and during epileptogenesis.
According to Li et al. [5], seizures cause blood–brain barrier (BBB) dis-
ruption, characterized by the invasion of leukocytes into the brain. Danjo
et al. [6] observed a loss of BBB integrity due to pentylenetetrazole (PTZ)-
induced seizures. These authors reported that BBB disruption occurs due
to high NO concentration, generated by neural nitric oxide synthase.
These data were previously conﬁrmed by our group [2] when we ob-
served high levels of NO and lymphocyte inﬁltrates into the brains of pa-
tients with TLE. Moreover, CRP action is related to the modulation of
polymorphonuclear cell function, complement system activation, and
the activation of phagocytosis [8]. With BBB disruption, CRP from blood
can enter into the brain, increasing the inﬂammatory process, which is
well-documented by several authors [25–28]. This process triggers a vi-
cious cycle in the brain since it is known that the inﬂammatory response
affects the generation of seizures as well as seizure severity [29].
An importantﬁnding of this study is the reduced levels of CRP and all
proinﬂammatory cytokines in blood of animals with chronic seizures,
treated with omega-3, when compared with those treated with vehicle
solution.
In addition, there is interest in the possible role of omega-3 fatty acid
as a potential agent in reducing the risk of SUDEP, since previous data
from our laboratory have demonstrated increased IL-6 levels in the
hearts of animals submitted to the pilocarpine model of epilepsy [30].
Omega-3 fatty acid reduces sodium and calcium ﬂux across excitable
membranes, reduces hippocampal excitability [31], and improvescognitive performance after seizures in rats. It has been shown that
omega-3 fatty acids have protective effects, preventing coronary heart
disease, reducing arrhythmias and thrombosis, lowering plasma triglyc-
eride levels, and reducing blood clotting tendency. Furthermore, sub-
stantial evidence from epidemiological and case–control studies
indicates that omega-3 reduces the risk of cardiovascular mortality [32].
Because SUDEP is thought to occur during or shortly after a seizure,
Taha et al. [33] have proposed that omega-3 fatty acids may reduce
the incidence of SUDEP through their anticonvulsant effects. Using the
pilocarpinemodel of epilepsy,wehave shown that chronic omega-3 ad-
ministration promotes neuroprotection and neuronal plasticity [17].
The occurrence of SUDEP has been associated with multifactorial
mechanisms, but a number of interictal, ictal, and postmortem cardiac
abnormalities account for the possibility of seizure-induced cardiogenic
SUDEP [34,35]. Our group showed that rats with epilepsy have a higher
resting heart rate than control rats [36], and a higher heart rate is a
major independent risk factor for cardiovascular death [37]. Basing on
this, the exact pathophysiology of SUDEP remains unknown, and one
of the best strategies to minimize the risk of SUDEP is to establish pre-
ventive measures [38]. Thus, if cardiovascular abnormalities during
and between seizures are directly related to a high frequency of
SUDEP, treatment with omega-3 appears to be a potential SUDEP-
prevention tool since substantial epidemiological evidence and case–
control and experimental studies indicate the beneﬁcial effects of
omega-3 consumption on the cardiovascular system and the CNS and
even in enhancing global quality of life of individuals with epilepsy [39].
CRP andproinﬂammatory cytokines are able to interactwith numer-
ous ligands associatedwith tissue response to cardiac injury and play an
important role in the pathogenesis of cardiovascular disease [9], and
ictal and postictal states are marked by sympathetic stimulation which
affects cardiopulmonary function [40,41]. Moreover, the peripheral
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Fig. 3. Plasma cytokine concentrationsmeasured bymultiplex analysis after omega-3 treatment in the chronic period. All cytokines (IL-1β, IL-6, TNF-αI, and L-10) that showed increased
levels in plasma during chronic period were reduced after omega-3 treatment when compared with the chronic group. ***p b 0.001.
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the establishment of treatment parameters is imperative. According to
this, through the utilization of animal models, we can observe if
omega-3 treatment was effective as anti-inﬂammatory therapy for
epilepsy, mainly in order to try decreasing the SUDEP occurrence.
However, future studies need to be done to evaluate the effect of
omega-3 fatty acid administration in association with antiepileptic
drugs on frequency and severity of seizures, as well as in cardiac remod-
eling parameters in people with refractory epilepsy.
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